BriaCell Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Lynwood Opportunities Master Fund(9.3%),Lynwood Capital Management Inc.(9.3%)等
BriaCell Therapeutics | 4:持股变动声明
BriaCell Therapeutics | 4:持股变动声明
BriaCell Therapeutics | 4:持股变动声明
BriaCell Therapeutics | 3:首次持股声明-董事 Bondarenko Jamieson
BriaCell Therapeutics | 3:首次持股声明-董事 Lustig Marc
BriaCell Therapeutics | 3:首次持股声明-高管 Del Priore Giuseppe
BriaCell Therapeutics | 3:首次持股声明-董事 Taub Rebecca
BriaCell Therapeutics | 3:首次持股声明-高管 Lopez-Lago Miguel A.
BriaCell Therapeutics | 3:首次持股声明-董事 Schmieg Martin E.
BriaCell Therapeutics | 3:首次持股声明-董事 Embro-Pantalony Vaughn C.
BriaCell Therapeutics | 3:首次持股声明-高管 Williams Williams V.
BriaCell Therapeutics | 3:首次持股声明-董事 Gross Jane A
BriaCell Therapeutics | 3:首次持股声明-高管 LEVIN GADI
BriaCell Therapeutics | SC 13G:超过5%持股股东披露文件
BriaCell Therapeutics | SC 13G:超过5%持股股东披露文件-Southwest Private Capital Inc.(5.1%)
BriaCell Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-CVI Investments, Inc.(3.6%),Heights Capital Management, Inc.(3.6%)
BriaCell Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Altium Capital Management, LP EIN:(4.7%),Altium Growth Fund, LP EIN:(4.7%)等
BriaCell Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-L1 Capital Global Opportunities Master Fund Ltd.(*%)
BriaCell Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Lind Global Macro Fund, LP(0.2%),Lind Global Partners LLC(0.2%)等
暂无数据